Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic cholangiocarcinoma (IHCC) individuals with fibroblast growth factor ...

The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.

HUTCHMED has announced the completion of patient enrollment in a Phase II trial for fanregratinib (HMPL-453), aimed at treating intrahepatic cholangiocarcinoma (IHCC) patients with FGFR2 fusion ...

The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics, and efficacy in advanced IHCC subjects who have FGFR2 fusion/rearrangement. Its primary ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

Hutchmed (HCM) announced that it has completed enrollment of its a Phase II trial of fanregratinib for intrahepatic cholangiocarcinoma patients ...

IHCC is a type of primary bile duct cancer, and FGFR2 fusion has been found in 10-15 percent of IHCC patients. HUTCHMED retains global rights to fanregratinib. HCM closed Wednesday's (Mar.

It was approved by the MHLW on the strength of a single-arm phase 2 trial (Study 201) that enrolled patients in Japan and China with FGFR2 gene fusion-positive unresectable BTC that had previously ...